Drug recall · October 27, 2021
GlipiZIDE Extended-Release Tablets recall
Why: Failed Dissolution Specifications: results were above specification.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054. Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)
- Lots / codes
Lot #: 194141, Exp. Date 03/31/2022
- Quantity
- 2,266 cartons
- Company
- American Health Packaging, Columbus, OH
- Distribution
- Nationwide within the USA
- Initiated
- September 17, 2021 · Voluntary: Firm initiated
- Classified
- October 20, 2021
- Reported
- October 27, 2021
- Ended
- June 8, 2023
- How notified
- N/A
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Glipizide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.